Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Heartflow, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders voted on board elections and auditor ratification. Two Class I directors, Julie A. Cullivan and John C.M. Farquhar, were elected to three-year terms ending at the 2029 annual meeting.
Shareholders cast 51,986,481 votes for and 6,046,730 withheld for Cullivan, and 52,277,825 for and 5,755,386 withheld for Farquhar, with 11,550,151 broker non-votes on each nominee. Stockholders also approved PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 68,735,861 votes for, 717,413 against, and 130,088 abstentions.
Heartflow, Inc. Chief Medical Officer Campbell Rogers reported an exercise of stock options into common shares. He exercised 10,000 stock options at an exercise price of $2.22 per share, receiving 10,000 shares of Heartflow common stock.
The filing shows Rogers holding 88,731 common shares directly after the transaction, plus additional indirect holdings in several trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust. Following the exercise, he also retains 71,633 stock options directly. The option exercise was carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 12, 2025.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported an open-market sale of 22,562 shares of common stock at $28.50 per share. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, and he continues to hold 496,835 shares directly, indicating a relatively small portion of his stake was sold.
HTFL filed a Form 144 notifying the sale of 22,562 shares of Common Stock tied to a Stock Option Exercise dated 06/25/2024.
The filing lists recent dispositions by John C M Farquhar in the prior three months: 12,837 shares on 03/10/2026 for $290,886.42; 9,725 shares on 03/18/2026 for $243,125.00; 22,562 shares on 04/10/2026 for $602,856.64; and 22,562 shares on 05/11/2026 for $657,005.44.
Heartflow, Inc. Chief Medical Officer Campbell Rogers reported an option exercise and related share sale in Common Stock. On May 18, 2026, he exercised stock options to acquire 9,219 shares at $19.00 per share, then sold 9,219 shares in an open-market transaction at $28.34 per share.
The filing shows he now holds 78,731 Common Stock shares directly. In addition, multiple trusts associated with him and his spouse report indirect holdings, including 50,754 shares by The Campbell Rogers Revocable Trust and 26,012 shares by a spouse’s trust. The footnotes state the option exercise and sale were carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 12, 2025.
HTFL Form 144 notice reports proposed sales of Common Stock by holders and broker details. The filing lists 86,240,828 shares and records recent dispositions including 47,615 shares and 16,918 shares on 03/19/2026 and 04/01/2026 with dollar amounts shown for those trades.
Bain Capital Life Sciences affiliate reports March 31, 2026 holdings in Heartflow. BCLS Fund III Investments, LP states it beneficially owns 10,448,158 shares of Common Stock, representing 12.18% of outstanding shares. The percentage is calculated using 85,757,754 shares outstanding as of February 28, 2026 per the issuer's Form 10-K.
The filing attributes shared voting and dispositive power to Bain Capital Life Sciences entities through managerial relationships; sole voting and dispositive power are reported as 0. Signature is by a partner of Bain Capital Life Sciences Investors, LLC.
Heartflow, Inc. reported strong first quarter 2026 results, with total revenue of $52.6 million, a 41% increase year-over-year, and raised its full year 2026 guidance. U.S. revenue was $48.3 million, up 42%, while international and other revenue reached $4.3 million, up 34%.
GAAP gross profit grew to $42.2 million and gross margin improved to 80.2% from 75.1%, helped by higher case volumes and AI-driven productivity gains. Total operating expenses increased to $71.7 million, including a $7.5 million non-cash impairment tied to optimizing facilities and moving the headquarters to San Francisco.
Net loss narrowed to $27.4 million, or $0.32 per share, from $32.3 million, while non-GAAP net loss improved to $13.3 million, or $0.16 per share. Adjusted EBITDA was a loss of $14.0 million. Heartflow ended March 31, 2026 with $254.9 million in cash, cash equivalents and investments, supporting continued investment in sales, technology, and clinical research.
Heartflow, Inc. director and Chief Executive Officer John C.M. Farquhar sold 22,562 shares of Common Stock in an open-market transaction at $29.12 per share on May 11, 2026. Following this sale, he directly holds 519,397 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.